<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2191">
  <stage>Registered</stage>
  <submitdate>26/11/2008</submitdate>
  <approvaldate>26/11/2008</approvaldate>
  <nctid>NCT00798993</nctid>
  <trial_identification>
    <studytitle>Effect of 25-hydroxyvitamin D and a Structured Exercise Program on Dialysis Patients</studytitle>
    <scientifictitle>The Effect of 25-hydroxyvitamin D Supplementation and a Structured Exercise Program on Exercise Capacity and Quality of Life in Dialysis Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SCGH25OHD2008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End Stage Kidney Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Structured Exercise program
Treatment: drugs - Cholecalciferol (25-Hydroxyvitamin D)
Other interventions - Usual exercise

Active Comparator: Structured exercise program - Participants will be randomised at 3 months into either this group or the comparator of usual exercise.

Experimental: Vitamin D - Cholecalciferol 2000U per day will be given to all participants for the duration of the study

Placebo Comparator: Usual exercise - Participants randomised to this arm, at 3 months, will continue on their usual exercise routine


Other interventions: Structured Exercise program
30 minutes on an exercise bicycle during every dialysis

Treatment: drugs: Cholecalciferol (25-Hydroxyvitamin D)
Cholecalciferol 2000U per day will be given for duration of study to all participants

Other interventions: Usual exercise
Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Exercise capacity - modified shuttle walk test</outcome>
      <timepoint>Basesline, 3 &amp; 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life with KDQOL</outcome>
      <timepoint>Baseline, 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quadriceps Strength</outcome>
      <timepoint>Baseline, 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum phosphate</outcome>
      <timepoint>baselibe, 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Feeling thermometer</outcome>
      <timepoint>Baseline, 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Timed up and go</outcome>
      <timepoint>baseline, 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Falls</outcome>
      <timepoint>continuous</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pulse wave velocity</outcome>
      <timepoint>baseline, 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bioimpedance</outcome>
      <timepoint>Baseline, 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Stable on dialysis for at least 3 months

          2. Able to obtain informed consent

          3. Medically stable

          4. Dialysis adequacy at target for small solute clearance (ie Kt/V&gt;1.2 or Urea reduction
             ratio&gt;65%)

          5. Serum 25-hydroxyvitamin D levels less than 75nmol/L at baseline</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Limb Amputation

          2. Impaired cognition

          3. Impaired vision

          4. Haemoglobin concentration &lt; 110g/L

          5. Change in Erythropoiesis stimulating agent dose over the last 2 months

          6. Unable or unwilling to comply with exercise program</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>19</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Sir Charles Gairdner Hospital - Perth</hospital>
    <postcode>6009 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Sir Charles Gairdner Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to examine the effect of 25 hydroxyvitamin D supplementation and a structured
      exercise program on the exercise capacity and quality of life of haemodialysis patients with
      25 hydroxyvitamin D insufficiency.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00798993</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ben Bull</name>
      <address>Sir Charles Gairdner Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>